MANDARA: Benralizumab v Mepolizumab in EGPA A#L14 #ACR23 @RheumNow P3, 52w RCT, 140 pts Remission rate: 59% Ben, 56.5% Mep Relapse rate 30% in both 86% Ben, 74% Mep had reduction of GC dose 50%+, 41% v 26% tapered off SAEs: 6% Ben, 13% Mep Concl: Non-inferiority of Ben v Mep https://t.co/mSIFsDq8eL